INTRODUCTION
Activation of platelets occurs through a complex series of reactions in response to vessel injury and plays an essential role in thrombosis. One agonist, adenosine diphosphate (ADP), plays a central role in platelet activation by acting as a cofactor in the platelet responses to physiological agonists, including thromboxane A2, collagen, and thrombin. ADP activates two surface expressed GPCRs, P2Y 1 and P2Y 12 (Gachet, 2005; Kunapuli et al., 2003) . The combined stimulation of P2Y 1 receptor (coupled to G q and PLCβ) and P2Y 12 receptor (negatively coupled to adenylyl cyclase through G i ) is necessary for the full platelet aggregation response to ADP with platelet activation initiated by the P2Y 1 receptor and amplified by P2Y 12 (Gachet, 2005) .
The attenuation of receptor-stimulated signal output upon sustained or recurrent agonist stimulation, a process known as desensitisation, is a crucial physiological mechanism of adaptation observed for many GPCRs. Since ADP plays a crucial role in platelet activation it likely that the responsiveness of P2Y 1 and P2Y 12 receptors is tightly regulated. Recently we showed that both P2Y 1 and P2Y 12 receptor responses desensitise in human platelets (Hardy et al., 2005) which may underlie the observed desensitisation of platelet responses following prolonged exposure to ADP (Baurand et al., 2000; Poole et al., 1993) .
Mechanisms underlying desensitization are complex and can involve phosphorylation of the receptor, uncoupling from G proteins, internalization, and ultimately intracellular down-regulation (Ferguson, 2001; von Zastrow, 2003) . We have recently discovered that ADP pre-treatment promotes P2Y 1 and P2Y 12 receptor desensitization by different kinase-dependent mechanisms. P2Y 1 , but not P2Y 12 , desensitization is mediated by protein kinase C (PKC) (Hardy et al., 2005) . In contrast, agonist-induced desensitization of the P2Y 12 receptor, but not P2Y 1 , is largely dependent on G protein-receptor coupled kinases (GRKs) activity.
It is now important to address several important questions that are raised by our previous work: (i) since platelets express multiple isoforms of PKC (Buensuceso et al., 2005; Crosby and Poole, 2002; Murugappan et al., 2004) , which isoforms are responsible for mediating homologous desensitisation of the P2Y 1 receptor? (ii) given the fact that platelets express multiple Gq-coupled receptors, each leading to MOL(2006/023549) 5 activation of PKC, can activation of PKC cause 'heterologous' regulation of P2Y 12 , and if so which isoforms of PKC are involved?, (iii) do the receptors themselves become phosphorylated by PKC?
Although our previous work had addressed only the roles of kinases in regulating functional desensitisation of the receptors, it is now also important to address their role in receptor internalisation and trafficking. In this study we address these questions and reveal distinct roles for PKC isoforms in the regulation of platelet P2Y receptor function and trafficking. MOL(2006/023549) 6
MATERIALS AND METHODS
Materials -Dulbecco's modified Eagle's medium (DMEM), Lipofectamine 2000 and fetal bovine serum were obtained from Life Technologies Inc. Radiochemicals were from Perkin Elmer Life Sciences.
Complete protease inhibitor tablets were from Roche. Anti-HA-monoclonal antibody (HA-11), goat antimouse fluorescein-conjugated secondary antibody (1:200), rhodamine-conjugated transferrin and lysotracker red were purchased from Molecular Probes. The bisindolylmaleimide GF109203X (2-[1-(3-dimethylaminopropyl)-1H-indol-3-yl]-3-(1H-indol-3-yl)-maleimide), Gö6976 [12-(2-Cyanoethyl)-6,7,12,13-tetrahydro-13-methyl-5-oxo-5H-indolo(2,3-a)pyrrolo(3,4-c)-carbazole] and rottlerin were from Calbiochem (Merck Biosciences Ltd, Nottingham, UK). All other reagents were from Sigma.
Adenovirus infection and cell culture -Expression vectors for dominant negative mutant (DNM) PKCα
(rabbit) and PKCδ (mouse) in adenoviruses were kind gifts from Professors Motoi Ohba and Toshio Kuroki, and have been described previously (Mitsutake et al., 2001; Ohba et al., 1998) . Adenoviruses were amplified in HEK293 cells and harvested after 72 hours, purified and viral titers estimated as previously described (Kanegae et al., 1994) . 1321N1 human astrocytoma cells stably expressing either hemagglutinin (HA)-tagged human P2Y 1 or P2Y 12 receptor were generated as previously described (Hardy et al., 2005) . Cells were maintained in DMEM supplemented with 10 % fetal bovine serum, 100 units ml -1 penicillin G, 100 µg ml -1 streptomycin sulfate and 400 µg/ml geneticin at 37 o C supplemented with in a humidified atmosphere of 95 % air, 5 % CO 2 . For adenoviral infection, 1321N1 cells were infected at between 50-200 pfu/cell in serum-free DMEM for 2 hours. Infection with empty vector β-gal adenovirus was used as control.
Receptor phosphorylation -Stably transfected cells in six well dishes were twice with phosphate-free DMEM and incubated for 90 min at 37 °C in the same media supplemented with 0.2 mCi/ml [ were performed at 4 °C unless otherwise stated. Cells were subsequently lysed and HA-tagged receptor immunoprecipitated using a monoclonal anti-HA antibody (HA-11) as previously described (Mundell et al., 2004) . Immune complexes were isolated by brief centrifugation, washed three times with immunoprecipitation buffer and eluted from beads by the addition of 20 µl electrophoresis sample buffer.
After fractionation by SDS-PAGE and transfer to a nitrocellulose membrane, phosphoproteins were visualised by autoradiography for 24-72 hr at -80 °C. Receptor immunoprecipitation was determined by reprobing membranes with a polyclonal anti-HA antibody / horse radish peroxidase-conjugated antirabbit IgG and visualization by enhanced chemiluminescence (ECL). The extent of receptor phosphorylation was quantified by densitometric analysis of resulting autoradiographs.
Western Blotting -Protein expression in 1321N1 cells and platelets was determined by western blotting.
Briefly, cells were lysed into ice-cold lysis buffer (HEPES 20 mM, pH 7.4, NaCl 200 mM, EDTA 10 mM, 1% Triton X-100, supplemented with Complete protease inhibitors), insoluble material discarded by centrifugation (13,000g, 5 min) and sodium dodecyl sulphate (SDS) loading buffer (63 mM Tris, pH 6.5, 100 mM dithiothreitol, 1% SDS, 11.6% glycerol and 0.02% bromophenol blue) added to the cell lysates.
Proteins were separated by SDS-PAGE. Gels were transferred to nitrocellulose membranes and blotted with PKC isoform specific antibodies for PKCα, β, ), δ and θ (Blass et al., 2002) .
Proteins were detected by enhanced chemiluminescence (ECL).
Measurement of cytosolic free calcium ([Ca

2+
] i ) in 1321N1 astrocytoma cells -The cytosolic free Ca 2+ concentration was determined using the fluorescent Ca 2+ indicator fura-2-acetoxymethyl ester (fura-2/AM) MOL(2006/023549) 8 as previously reported (Hardy et al., 2005) . Briefly transfected cells were grown on poly-L-lysine coated glass coverslips and used at ~ 60% confluence. Cells were washed twice with Locke's solution (154 mM NaCl, 5.6 mM KCL, 1.2mM MgCl 2 , 2.2 mM CaCl 2 , 5 mM HEPES, 10 mM glucose, pH 7.4) and incubated with fura-2/AM (3 µM) at 37 ° C for 60 mins. Glass coverslips were mounted into a quartz cuvette and placed into a thermostatically-controlled cell holder at 37 °C. Cells were continuously perfused with Lockes solution. Fluorescence was measured at 340 and 380 nM excitation and 510 nM emission. ADP (0.1 -1 µM) was perfused onto cell monolayers as required. [Ca 2+ ] i was determined from ratiometric data as previously described (Grynkiewicz et al., 1985) .
Measurement of cAMP accumulation in 1321N1 astrocytoma cells -Cells infected with PKC-DNM
adenoviruses, or β-gal alone controls, as described above were grown to 80% confluency and exposed to a desensitising dose of ADP (1 nM; 15 min) or PMA (1 µM; 15 min) in the presence of the phosphodiesterase inhibitor Ro201724 (250 µM). Apyrase (0.2 unit /ml) was then added directly to each well and incubated for 1 min at 37 °C to remove the desensitising ADP. Cells were then washed and forskolin (1 µM) added in the absence or presence of ADP and plates incubated at 37°C for 10 minutes.
Endogenous β 2 adrenoceptor responses were also examined in 1321N1 cells by measuring isoproterenol (1 µM)-stimulated cAMP accumulation. Cyclic AMP accumulation was terminated by addition of ice cold 100 % trichloroacetic acid and supernatant neutralized with 1 M NaOH and TE buffer. Cyclic AMP levels were determined as previously described (Mundell et al., 1997) . Data are expressed as cAMP production (pmol cAMP/well) or as % inhibition of forskolin stimulated adenylyl cyclase.
Internalization of HA-P2Y 1 and HA-P2Y 12 in 1321N1cells -HA-tagged surface receptor loss was assessed by ELISA as described previously (Daunt et al., 1997; Mundell et al., 2000) . Cells were split into 24-well tissue culture dishes coated with 0.1 mg ml -1 poly-L-lysine. Twenty-four hours later, cells were incubated with DMEM containing apyrase (0.1 unit/ ml) for 1 hour at 37 °C , washed and then pre-treated with the (Daunt et al., 1997; Mundell et al., 2000) , and expressed as either % surface receptor or % loss of surface receptor with the background signal from controls subtracted.
Preparation of human platelets -Human blood was drawn from healthy, drug-free volunteers on the day of the experiment. Acid citrate dextrose (ACD: 120 mM sodium citrate, 110 mM glucose, 80 mM citric acid, used at 1:7 vol/vol) was used as anticoagulant. Platelet rich plasma (PRP) was prepared by centrifugation at 200g, for 17 min and platelets were then isolated by centrifugation for 10 min at 1000g, in the presence of 0.02 U/ml apyrase and prostaglandin E 1 (PGE 1 ; 140 nM) for all assays other than measurement of intracellular cyclic AMP (cAMP) where PGE 1 was omitted. The pellet was resuspended to a density of 4x10 8 platelets/ml in a modified Tyrodes-HEPES buffer (145 mM NaCl, 2.9 mM KCl, 10 mM HEPES, 1 mM MgCl 2 , 5 mM glucose, pH 7.3). To this platelet suspension 10 µM indomethacin and 0.02 U/ml apyrase were added, and a 30 min resting period was allowed before stimulation.
Measurement of cytosolic free calcium ([Ca
2+
] i ) in platelets -Measurement of cytosolic calcium was performed as previously described (Poole et al., 1995) . Briefly, 3 µM Fura-2-AM was added to platelet rich plasma, and incubated at 37 °C for 45 min in the presence of 10 µM indomethacin. Platelets were centrifuged and re-suspended in modified Tyrodes. Platelets were treated for 15 min with the PKC inhibitors GF109203X (2 µM), Gö6976 (1 µM) Rottlerin (10 µM) or vehicle alone. ADP (10 µM)-induced calcium responses were subsequently measured at 37 °C in PMA (1 µM; 15 min) and non PMAtreated platelets using a Hitachi F-4500 spectrofluorimeter with fluorescence excitation made at 340 nm and 380 nm and emission at 510 nm.
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Measurement of cAMP levels in platelets -Platelets were treated for 15 min with the PKC inhibitors GF109203X (2 µM), Gö6976 (1 µM), rottlerin (10 µM) or vehicle alone. PMA (1 µM; 15 min) and non PMA-treated platelets were stimulated in the presence of the phosphodiesterase inhibitor IBMX (100 µM)
± forskolin (1 µM) in the absence or presence of ADP (10 µM) for 5 min at 37 °C. Cyclic AMP accumulation was terminated by addition of ice cold 100 % trichloroacetic acid (TCA) and samples were left to lyse on ice for 1-2 hrs. The resulting samples were spun at 4000 g for 5 min and the cAMPcontaining supernatant neutralized with 1 M NaOH and TE buffer (50 mM Tris-HCl, 4 mM EDTA, pH 7.4). Cyclic AMP levels were subsequently determined in each sample using a binding assay as previously described (Mundell et al., 1997) . Data are presented as either % inhibition of forskolinstimulated adenylyl cyclase. receptor runs at a considerably higher apparent molecular weight than may be predicted from its primary amino acid sequence, due to extensive N-linked glycosylation (Zhong et al., 2004 (Hardy et al., 2005) . Over-expression of either isoform-specific dominant negative mutant (DNM) did not significantly attenuate agonist-induced desensitisation (Fig. 3A) . A reduction in P2Y 1 receptor desensitisation was only apparent in cells co-expressing both PKCα-and PKCδ-DNM (Fig.   3A ). Pre-treatment with PMA (1 µM; 15 min) significantly attenuated subsequent agonist-induced P2Y 1 receptor activity. As with the homologous desensitisation of P2Y 1 receptor activity, heterologous PMAinduced desensitisation was only attenuated when both PKCα-and PKCδ-DNM were co-expressed.
Radioligand binding in human platelets -
Studies examining the G i -coupled P2Y 12 purinergic receptor revealed that ADP-induced inhibition of forskolin-stimulated adenylyl cyclase (ADP induced an 80% inhibition of response, consistent with previous studies (Hardy et al., 2005) ) was reduced following PMA (1 µM; 15 min) pre-treatment to a similar extent to that found in ADP (10 nM; 15 min) desensitised cells (Fig. 3B) . Actual numbers are shown in Fig. 3B (i) and normalised data is shown in Fig. 3B (ii). Data from Fig. 3B (Mundell et al., 2004) . Stimulation with either ADP (10 µM; 5 min) or PMA (1 µM; 15 min) induced internalization of both P2Y 1 and P2Y 12 receptors (Fig. 4) . The rate of internalisation is shown in Fig. 4 (Hardy et al., 2005) .
Therefore as expected pre-treatment with PMA resulted in a significant reduction in subsequent ADPpromoted P2Y 1 receptor-mediated calcium response (Fig. 5A) . Inhibition of PKC with GF109203X (2 µM), a non-selective PKC inhibitor significantly attenuated P2Y 1 receptor desensitisation. Pre-treatment with Gö6976 (1 µM), which inhibits calcium-dependent classical PKC isoforms (Martiny-Baron et al., MOL(2006/023549) 15 1993), including PKCα, and rottlerin (10 µM), a PKCδ isoform selective inhibitor (Gschwendt et al., 1994) , were unable to attenuate PMA promoted P2Y 1 -receptor desensitisation (Fig. 5A ). Importantly however, pre-treatment with both Gö6976 and rottlerin was able to partially attenuate the desensitisation of P2Y 1 receptor activity. Stimulation of PKC with PMA also decreased ADP-induced P2Y 12 receptormediated inhibition of forskolin stimulated adenylyl cyclase (Fig. 5B(i) shows actual numbers and Fig.   5B (ii) shows normalised data) to a level comparable to that induced by ADP pre-treatment (Hardy et al., 2005) . Pre-treatment with either GF109203X or rottlerin attenuated PMA-induced P2Y 12 receptor desensitisation whilst Gö6976 had no effect on desensitisation of the P2Y 12 response (Fig. 5B) . Therefore stimulation of PKC activity can promote the heterologous desensitisation of both P2Y 1 and P2Y 12 receptor responses in human platelets. Finally, in order to demonstrate that, in the platelet system the Gq-coupled P2Y 1 receptor may regulate P2Y 12 , we chose to investigate the effect of P2Y 1 receptor blockade upon ADP-induced desensitisation of the P2Y 12 receptor response. Figure 6 shows that pre-treatment of platelets with the P2Y 1 receptor antagonist A3P5P (1 mM) does not attenuate P2Y 12 -mediated inhibition of adenylyl cyclase, but that in the presence of A3P5P the ADP-induced desensitisation of the P2Y 12 receptor is reduced, indicating partial heterologous regulation of P2Y 12 by the P2Y 1 receptor.
Internalization of P2Y 1 and P2Y 12 receptors in human platelets -In order to study the internalization of purinergic receptors in human platelets we made use of the non-specific P2 ligand 2MeSADP (Takasaki et al., 2001 ). Importantly we chose to use formaldehyde-fixed platelets for our study. The reason for doing so was to be able to avoid complications to the binding assay produced by released ADP and ATP, which would compete with radioligand for binding sites. This has been a problem in other studies, and the use of fixed platelets to overcome this problem has been validated previously (Agarwal et al., 1989; Jefferson et al., 1988 (Fig. 7A) . Further studies showed that the P2Y 12 receptor internalised much more rapidly than the P2Y 1 receptor although by 30 minutes the relative surface expression of each receptor was comparable (Fig. 7B) . Therefore, as in 1321N1 cells, both the P2Y 1 and P2Y 12 purinergic receptors internalise in a rapid agonist-dependent manner in human platelets.
PKC-dependent regulation of P2Y 1 and P2Y 12 receptor surface receptor expression and internalization in
human platelets -In order to address the role PKC may play in this process we used the PKC inhibitors, GF109203X, Gö6976 and rottlerin described above. Interestingly pre-treatment of platelets with any of these inhibitors significantly increased the number of P2Y 1 binding sites, with GF109203X the most potent (Fig. 7C) . Pre-treatment with GF109203X or rottlerin also significantly increased the number of P2Y 12 receptor binding sites whilst Gö6976 had no significant effect (Fig. 7C) (Hipkin et al., 2000; Mundell et al., 2002; Xiang et al., 2001 ). Initially we demonstrated that both P2Y 1 and P2Y 12 receptors underwent ADP-induced phosphorylation and that activation of PKC by PMA also promoted phosphorylation of both receptor subtypes. To our knowledge this is the first demonstration that either of these GPCRs can be phosphorylated in an agonist-dependent or independent manner. The non-selective PKC inhibitor GF109203X attenuated ADP-stimulated P2Y 1 receptor phosphorylation consistent with our recent demonstration that PKC regulates agonist-induced P2Y 1 receptor activity (Hardy et al., 2005) . Although PKC can activate GRK2 and 3 isoforms, promoting their translocation to the cell membrane (Winstel et MOL(2006 /023549) 19 al., 1996 , these kinases are unlikely to mediate agonist-independent PMA-dependent phosphorylation since GRKs only phosphorylate agonist-occupied receptors (Penn et al., 2000; Pitcher et al., 1998) . We would therefore propose, from the present data, that PKC isoforms lie directly upstream of phosphorylation of P2Y 1 and P2Y 12 receptors, at least in 1321N1 cells. These experiments were undertaken in P2Y receptor null 1321N1 cells stably expressing epitope tagged versions of both receptors.
The lack of specific and high affinity P2Y receptor antibodies with which to isolate either receptor from platelet cell membranes prevents similar studies in human platelets at this time. There are however a number of putative PKC phosphorylation sites located within the C-terminus of both receptors, including Thr 339 in the P2Y 1 receptor, which regulates PKC-dependent desensitisation (Fam et al., 2003) , and may be important as such in platelets.
Since phosphorylation of agonist-unoccupied receptors has been implicated in desensitisation and internalization of many GPCRs we sought to determine its functional significance and to identify the specific PKC isoforms responsible. Interestingly, PMA pre-treatment attenuated subsequent ADPstimulated P2Y 1 and P2Y 12 receptor activity and promoted agonist-independent surface receptor loss, the first demonstration of heterologous regulation of these GPCRs. Over-expression of dominant negative mutant (DNM) catalytically inactive forms of PKCα and PKCδ, the two PKC isoforms common to both platelets and 1321N1 cells, revealed that both isoforms regulated the agonist and PMA-induced desensitisation and internalization of P2Y 1 receptors since an attenuation of receptor desensitisation and surface receptor loss was only evident on co-expression of both DNMs. ADP-induced P2Y 12 receptor desensitisation is regulated by GRKs and for this receptor we have ruled out any contribution from PKCs since expression of DNM PKC constructs did not have any effect (Hardy et al., 2005) . Interestingly, however, we found that heterologous PMA-promoted desensitisation and internalization of P2Y 12 receptor function was regulated by PKCδ alone. Importantly also we now show that not only receptor-independent activation of PKC, but also activation of PKC by endogenous M 3 muscarinic receptors in 1321N1 cells is able to induce internalisation of both P2Y 1 and P2Y 12 receptors (Fig. 4A&B) showed in Fig. 6 that in platelets P2Y 1 receptors contribute partially to desensitisation of P2Y 12 receptors in a heterologous manner. Since platelets lack a nucleus and significant protein synthetic machinery, approaches to disrupt or reduce endogenous protein function e.g. expression of dominant negative mutants are not viable at present. Therefore in order to determine the PKC isoforms that regulate purinergic receptor function we used three PKC inhibitors, GF109203X (2 µM), a potent inhibitor of conventional and novel PKC isoforms (Toullec et al., 1991) , Gö6976 (1 µM), an inhibitor with IC 50 s in the nanomolar range for calcium-dependent PKC isoforms (Martiny-Baron et al., 1993) , including PKCα, and rottlerin (10 µM) which selectively inhibits the calcium-independent PKC isoforms, inhibiting PKCδ with an IC 50 of approximately 5 µM; 10-30 fold higher concentrations are required to inhibit conventional PKC isoforms (Gschwendt et al., 1994) . Using these selective inhibitors we found that as in 1321N1 cells, classical and novel isoforms of PKC can regulate the heterologous desensitisation of P2Y 1 receptor activity whilst only PKCδ was capable of desensitising P2Y 12 receptor activity in an agonist-independent manner.
In order to examine changes in purinergic receptor surface expression in human platelets we used the P2Y receptor radioligand (Baurand et al., 2000) . This is important since we had chosen to use formaldehyde-fixed platelets for our study. In our study, following stimulation with ADP the number of binding sites for both P2Y 1 and P2Y 12 receptors was significantly reduced. Recent investigations, in agreement with our own, indicate that agonist pre-treatment with ADPβS also reduced the number of P2Y 1 receptor binding sites in stably transfected 1321N1 cells (Baurand et al., 2000; Baurand et al., 2005) .
This was paralleled in the study of Baurand et al. (2005) by ADP-induced internalisation of P2Y 1 receptors in platelets. By contrast however, P2Y 12 receptor surface expression was reported by these authors not to change following pre-treatment of 1321N1 cells with ADPβS, and only to internalise transiently and very rapidly upon treatment of platelets with 5 µM ADP. The data relating to the P2Y 12 receptor are therefore in contrast to those of the present study, where we show a more sustained internalisation in platelets and 1321N1 cells. The reasons for the discrepancy between our data and those of Baurand et al. (2005) are not clear, although there are a number of methodological differences between the two studies. First, it should be noted that since ADPβS is less potent at P2Y 12 receptors than P2Y 1 (Takasaki et al., 2001) and is a partial agonist at the P2Y 12 purinergic receptor (Cusack and Hourani, 1981) , it may be unable to promote full internalization of this receptor (Clark et al., 1999) . Additionally, the study of Baurand et al. (2005) used GFP-tagged receptor expressed in 1321N1 cells (Baurand et al., 2005) , in contrast to the HA tag used in our study. The relatively bulky GFP tag may unpredictably alter signalling and trafficking properties of the receptor. The platelet studies also differ in that Baurand et al. (2005) use an immunogold transmission electron microscopic approach whereas the present study uses a radioligand binding approach. These methodological differences may explain the different results obtained for P2Y 12 receptors. Interestingly, in our study, pre-treatment with PMA also reduced P2Y 1 and P2Y 12 receptor surface expression. This is the first demonstration that heterologous activation of PKC can promote the internalisation of P2Y receptors in human platelets.
Interestingly in the absence of agonist treatment the surface expression of both receptors was increased following pre-treatment with inhibitors of PKC (Fig. 7C) and it seems likely therefore that basal PKC (Crosby and Poole, 2003; Murugappan et al., 2005; Murugappan et al., 2004; Pula et al., 2005) and their different modes of activation may in turn determine their ability to phosphorylate downstream targets. It is also unclear why PKCδ specifically attenuates P2Y 12 receptor signalling. The activity of PKC isoforms is tightly regulated by multiple molecular mechanisms including interaction with binding-partner proteins (Poole et al., 2004) . A greater understanding of the protein-protein interactions between particular PKC isoforms and membrane-associated anchoring protein, which serve to recruit the PKC isoforms to distinct subcellular compartments, in close proximity to receptor target substrates should prove useful in unravelling patterns of GPCR / PKC isoform specificity.
In conclusion, since ADP performs a pivotal role in the formation of stable platelet aggregates, the activity of purinergic receptors may maintain the delicate balance between rest and activation that underlies platelet sensitivity. Our results show for the first time that regulation of platelet purinergic receptor expression and activity by specific PKC isoforms may play a significant role in haemostatic function. In (A) platelets were treated with ADP (10 µM) for 10 minutes. Data are expressed as receptor specific 
